Selective blockade of serotonin(2C) receptor enhances Fos expression specifically in the striatum and the subthalamic nucleus within the basal ganglia

Philippe De Deurwaerdère, Catherine Le Moine, Marie-Françoise Chesselet
Neuroscience Letters. 2010-01-01; 469(2): 251-255
DOI: 10.1016/j.neulet.2009.12.006

PubMed
Read on PubMed



1. Neurosci Lett. 2010 Jan 22;469(2):251-5. doi: 10.1016/j.neulet.2009.12.006. Epub
2009 Dec 11.

Selective blockade of serotonin 2C receptor enhances Fos expression specifically
in the striatum and the subthalamic nucleus within the basal ganglia.

De Deurwaerdère P(1), Le Moine C, Chesselet MF.

Author information:
(1)Université de Bordeaux, Unité Mixte de Recherche-Centre National de la
Recherche Scientifique (UMR-CNRS) 5227, 146 rue Léo Saignat, B.P. 28, 33076
Bordeaux Cedex, France.

Serotonin(2C) (5-HT(2C)) receptors are widely expressed in the basal ganglia, a
group of brain regions involved in the control of motor behavior. However, it
remains unclear whether their tonic influence on neuronal activity is distributed
in these regions. We have addressed this question by measuring the product of the
proto-oncogene c-Fos in rats after peripheral administration of the non-selective
5-HT antagonist mianserin, the 5-HT(2C/2B) antagonist SER-082 or the selective
5-HT(2C) antagonist SB 243213. The intraperitoneal administration of 1mg/kg of SB
243213 or SER-082, but not mianserin, enhanced Fos-immunoreactive cells in the
subthalamic nucleus and the striatum, primarily its medial portion. None of these
treatments significantly affected Fos expression in the external globus pallidus,
the entopeduncular nucleus (the internal globus pallidus in primate) or the
substantia nigra pars reticulata. The data suggest that selective blockade of
5-HT(2C) receptors is necessary to unmask a tonic regulation of neuronal activity
by this receptor in the basal ganglia and that this effect is restricted to the
two structures receiving cortical entries, the striatum and the subthalamic
nucleus.

(c) 2009 Elsevier Ireland Ltd. All rights reserved.

DOI: 10.1016/j.neulet.2009.12.006
PMID: 20004702 [Indexed for MEDLINE]

Know more about